Compare PLETHICO PHARMA with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs DIVIS LABORATORIES - Comparison Results

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA DIVIS LABORATORIES PLETHICO PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x -1.1 32.6 - View Chart
P/BV x 0.0 7.4 0.2% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 PLETHICO PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
DIVIS LABORATORIES
Mar-18
PLETHICO PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs3951,142 34.6%   
Low Rs31533 5.9%   
Sales per share (Unadj.) Rs604.4146.6 412.3%  
Earnings per share (Unadj.) Rs32.533.0 98.3%  
Cash flow per share (Unadj.) Rs51.338.4 133.6%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.2 0.0%  
Book value per share (Unadj.) Rs473.6222.8 212.5%  
Shares outstanding (eoy) m34.08265.47 12.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.45.7 6.2%   
Avg P/E ratio x6.625.3 25.9%  
P/CF ratio (eoy) x4.221.8 19.0%  
Price / Book Value ratio x0.53.8 12.0%  
Dividend payout %030.3 0.0%   
Avg Mkt Cap Rs m7,262222,318 3.3%   
No. of employees `000NA10.8 0.0%   
Total wages/salary Rs m1,5964,561 35.0%   
Avg. sales/employee Rs ThNM3,616.0-  
Avg. wages/employee Rs ThNM423.8-  
Avg. net profit/employee Rs ThNM814.9-  
INCOME DATA
Net Sales Rs m20,59838,915 52.9%  
Other income Rs m3861,134 34.1%   
Total revenues Rs m20,98440,049 52.4%   
Gross profit Rs m2,81812,617 22.3%  
Depreciation Rs m6421,425 45.1%   
Interest Rs m1,59313 11,978.9%   
Profit before tax Rs m96912,313 7.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1383,543 -3.9%   
Profit after tax Rs m1,1078,770 12.6%  
Gross profit margin %13.732.4 42.2%  
Effective tax rate %-14.328.8 -49.7%   
Net profit margin %5.422.5 23.8%  
BALANCE SHEET DATA
Current assets Rs m18,87745,351 41.6%   
Current liabilities Rs m11,8966,507 182.8%   
Net working cap to sales %33.999.8 34.0%  
Current ratio x1.67.0 22.8%  
Inventory Days Days36127 28.4%  
Debtors Days Days19895 207.9%  
Net fixed assets Rs m9,86121,160 46.6%   
Share capital Rs m341531 64.2%   
"Free" reserves Rs m12,33158,625 21.0%   
Net worth Rs m16,13959,156 27.3%   
Long term debt Rs m4,7060-   
Total assets Rs m33,14667,832 48.9%  
Interest coverage x1.6926.8 0.2%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.60.6 108.3%   
Return on assets %8.112.9 62.9%  
Return on equity %6.914.8 46.3%  
Return on capital %12.320.8 59.0%  
Exports to sales %21.40-   
Imports to sales %15.221.8 69.8%   
Exports (fob) Rs m4,402NA-   
Imports (cif) Rs m3,1368,485 37.0%   
Fx inflow Rs m4,40232,359 13.6%   
Fx outflow Rs m3,1849,042 35.2%   
Net fx Rs m1,21923,317 5.2%   
CASH FLOW
From Operations Rs m2,4377,759 31.4%  
From Investments Rs m-6,265-4,783 131.0%  
From Financial Activity Rs m2,490-3,142 -79.3%  
Net Cashflow Rs m-1,337-166 805.5%  

Share Holding

Indian Promoters % 82.7 52.0 159.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 11.8 36.4%  
FIIs % 5.5 19.0 28.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 17.2 43.6%  
Shareholders   10,665 31,796 33.5%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   STRIDES PHARMA SCIENCE  ELDER PHARMA  ALEMBIC LTD  ALEMBIC PHARMA  WOCKHARDT  

Compare PLETHICO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (1QFY20); Net Profit Up 0.4% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY19); Net Profit Up 10.6% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 10.6% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY19); Net Profit Up 68.9% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 68.9% YoY). Sales on the other hand came in at Rs 13 bn (up 29.4% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES 2017-18 Annual Report Analysis (Annual Result Update)

Jan 1, 2019 | Updated on Jan 1, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

DIVIS LABORATORIES Announces Quarterly Results (2QFY19); Net Profit Up 92.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 92.3% YoY). Sales on the other hand came in at Rs 13 bn (up 44.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 8-QTR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS